Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 17/20 | 0.54 |
| ▸ | CCNB2 | O95067 | 2/20 | 0.50 |
| ▸ | CDK1 | P06493 | 2/20 | 0.50 |
| ▸ | CCNB1 | P14635 | 2/20 | 0.50 |
| ▸ | CCNB3 | Q8WWL7 | 2/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | GSK3B | P49841 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphoric Acid SCHEMBL28527815 | 0.91 | RIPK1 (0.50) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL14838870 | 0.80 | CCNB2 (0.65) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31704117 | 0.80 | CCNB2 (0.65) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL31374627 | 0.77 | RIPK1 (0.58) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL451378 | 0.77 | RIPK1 (0.50) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL6016016 | 0.76 | GSK3B (0.58) | GSK3BCDK5CDK5R1 | |
| SCHEMBL31537211 | 0.76 | GSK3B (0.58) | GSK3BCDK5CDK5R1 | |
| SCHEMBL1778505 | 0.74 | RIPK1 (0.74) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL20670460 | 0.74 | RIPK1 (0.54) | RIPK1CCNB2CDK1CCNB1CCNB3 | |
| SCHEMBL142585 | 0.73 | DAO (0.47) | RIPK1CCNB2CDK1CCNB1CCNB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-100364992-C | A class of pyrrolo-naphthyridine derivatives | UNIV YUNNAN (CN) | 2008-01-30 | — | — | CN | claimed |
| US-7297689-B2 | Method for preparing peritoneal dialysate | Kurokawa, Kiyoshi (JP) | 2007-11-20 | — | — | US | claimed |
| CN-1821246-A | A class of pyrrolo-naphthyridine derivatives | UNIV YUNNAN (CN) | 2006-08-23 | — | — | CN | claimed |
| US-20050267045-A1 | Method for preparing peritoneal dialysate | TOSHIO MIYATA | 2005-12-01 | — | — | US | claimed |
| US-6919326-B1 | Carbonyl-stress improving agent and peritoneal dialysate | Miyata, Toshio (JP) | 2005-07-19 | — | — | US | claimed |
| US-12421243-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | PRINTNET KERESKEDELMI ÉS SZOLGÁLTATÓ KFT. (HU) | 2025-09-23 | — | — | US | disclosed |
| CN-112334191-B | Pharmaceutically effective compounds for selectively inhibiting myosin 2 isoforms | 普林特商业服务有限公司 | 2024-12-10 | — | — | CN | disclosed |
| US-20240270752-A1 | PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS | EÖTVÖS LORÁND TUDOMÁNYEGYETEM (HU) | 2024-08-15 | — | — | US | disclosed |
| CN-117924285-A | Pharmaceutically effective compounds for selectively inhibiting myosin 2 isoforms | 普林特商业服务有限公司 | 2024-04-26 | — | — | CN | disclosed |
| CN-110234401-B | Methods and compositions for adaptive immunomodulation | 德克萨斯大学系统董事会 | 2024-03-01 | — | — | CN | disclosed |
| US-11845758-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | PRINTNET KERESKEDELMI ÉS SZOLGÁLTATÓ KFT. (HU) | 2023-12-19 | — | — | US | disclosed |
| US-20230339959-A1 | PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS | EÖTVÖS LORÁND TUDOMÁNYEGYETEM (HU) | 2023-10-26 | — | — | US | disclosed |
| CN-1821246-A | A class of pyrrolo-naphthyridine derivatives | UNIV YUNNAN (CN) | 2006-08-23 | — | — | CN | disclosed |
| US-20050267045-A1 | Method for preparing peritoneal dialysate | TOSHIO MIYATA | 2005-12-01 | — | — | US | disclosed |
| US-6919326-B1 | Carbonyl-stress improving agent and peritoneal dialysate | Miyata, Toshio (JP) | 2005-07-19 | — | — | US | disclosed |
| CN-1192800-C | Blood carbonyl compound trapping agent | TOSHIO MIYATA (JP) | 2005-03-16 | — | — | CN | disclosed |
| EP-1228756-A1 | AGENTS FOR RELIEVING CARBONYL STRESS | Kurokawa, Kiyoshi (JP) | 2002-08-07 | — | — | EP | disclosed |
| EP-1219302-A1 | TRAPPING AGENT FOR BLOOD CARBONYL COMPOUNDS | Kurokawa, Kiyoshi (JP) | 2002-07-03 | — | — | EP | disclosed |
| CN-1356912-A | Blood carbonyl compound trapping agent | TOSHIO MIYATA (JP) | 2002-07-03 | — | — | CN | disclosed |
| EP-1108434-A1 | DRUGS FOR RELIEVING CARBONYL STRESS AND PERITONEAL DIALYSATES | Kurokawa, Kiyoshi (JP) | 2001-06-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11845758-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | MYH2, MYLK2, MYO1B | RIPK1 4859/4885CCNB2 313/4885CDK1 796/4885 |
| US-20240270752-A1 | PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS | MYH2, MYLK2, MYO1B | RIPK1 4859/4885CCNB2 313/4885CDK1 796/4885 |
| US-12421243-B2 | Pharmaceutically effective compounds inhibiting selectively the myosin 2 isoforms | MYH2, MYLK2, MYO1B | RIPK1 4859/4885CCNB2 313/4885CDK1 796/4885 |
| US-20230339959-A1 | PHARMACEUTICALLY EFFECTIVE COMPOUNDS INHIBITING SELECTIVELY THE MYOSIN 2 ISOFORMS | MYH2, MYLK2, MYO1B | RIPK1 4859/4885CCNB2 313/4885CDK1 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.